BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 4006047)

  • 1. Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.
    Ramu A; Fridkin M; Steinherz R
    Cancer Chemother Pharmacol; 1985; 15(1):31-4. PubMed ID: 4006047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
    Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
    Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells.
    Mandelbaum-Shavit F; Ramu A
    Cell Biol Int Rep; 1987 May; 11(5):389-96. PubMed ID: 3607890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells by dipyrone.
    Chitnis MP; Kamath NS
    Oncology; 1987; 44(1):47-50. PubMed ID: 3561929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
    Ramu A; Fuks Z; Gatt S; Glaubiger D
    Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
    Ramu A; Shan TC; Glaubiger D
    Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
    Capranico G; Dasdia T; Zunino F
    Int J Cancer; 1986 Feb; 37(2):227-31. PubMed ID: 3943921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
    Kamath NS; Chitnis MP
    Oncology; 1990; 47(2):166-9. PubMed ID: 2314829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential agglutination of P388 adriamycin-sensitive and P388 adriamycin-resistant leukemia cells.
    Basrur VS; Chitnis MP; Menon RS
    Oncology; 1983; 40(3):202-4. PubMed ID: 6843944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
    Ganapathi R; Grabowski D; Schmidt H
    Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
    Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
    Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Turinic R; Valenzuela R
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):799-806. PubMed ID: 6540180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
    Hait WN; Pierson NR
    Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
    Ramu A; Cohen L; Glaubiger D
    Cancer Res; 1984 May; 44(5):1976-80. PubMed ID: 6324993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line.
    Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K
    Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine.
    Inaba M; Fujikura R; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1981 Aug; 30(15):2191-4. PubMed ID: 7295334
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
    Satyamoorthy K; Deshpande SS; Chitnis MP
    Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.